The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome
Pharma & Human Health

Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome

FEB 12, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025
Changes in microbiome predict risk for sexually transmitted disease
Infectious Disease & AMR

Changes in microbiome predict risk for sexually transmitted disease

JAN 22, 2025
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Finance

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

JAN 15, 2025
Penn Medicine launches a pioneering project to study the human virome puzzle
Animal Health

Penn Medicine launches a pioneering project to study the human virome puzzle

JAN 14, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
A new way to determine whether a species will successfully invade an ecosystem
Pharma & Human Health

A new way to determine whether a species will successfully invade an ecosystem

JAN 7, 2025
Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics
Biotics and Supplements

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

DEC 17, 2024
Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Clinical & Manufacturing

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

DEC 17, 2024
Possible colon cancer vaccine target uncovered in bacteria
Gastrointestinal

Possible colon cancer vaccine target uncovered in bacteria

DEC 12, 2024